-
公开(公告)号：US09271786B2
公开(公告)日：2016-03-01
申请号：US14330671
申请日：2014-07-14
CPC classification number: A61B18/10 , A61B18/082 , A61B18/1206 , A61B18/1233 , A61B18/1492 , A61B2017/00575 , A61B2018/00351 , A61B2018/0041 , A61B2018/00446 , A61B2018/00577 , A61B2018/00642 , A61B2018/00702 , A61B2018/0075 , A61B2018/00791 , A61B2018/00875 , A61B2218/002 , A61M25/0071 , A61N1/205
Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.
-
公开(公告)号：US20160151105A1
公开(公告)日：2016-06-02
申请号：US15014991
申请日：2016-02-03
Inventor： Samuel J. Asirvatham , Arshad Jahangir , Bernard B.C. Lim , Kalpathi L. Venkatachalam
CPC classification number: A61B18/10 , A61B18/082 , A61B18/1206 , A61B18/1233 , A61B18/1492 , A61B2017/00575 , A61B2018/00351 , A61B2018/0041 , A61B2018/00446 , A61B2018/00577 , A61B2018/00642 , A61B2018/00702 , A61B2018/0075 , A61B2018/00791 , A61B2018/00875 , A61B2218/002 , A61M25/0071 , A61N1/205
Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.
Abstract translation: 医疗器械的一些实施例可以被配置为通过在医疗过程期间将负电荷偏压递送到与血液或身体组织相接触的导电表面来减少凝结物的形成。 在仪器 - 血液界面处应用负电荷可以减少纤维蛋白原沉积和凝结物的形成，因为纤维蛋白原分子通常在中性pH水平下带负电荷。 此外，仪器的一些实施例可以被配置为用RGD / ClfA肽，碳酸氢盐溶液（或其它高pH溶液）或两者冲洗仪器 - 血液界面，以进一步排斥纤维蛋白原，从而抑制凝块的形成。 因此，医疗器械的一些实施例可以显着降低特定医疗过程中血栓栓塞的风险。
-
公开(公告)号：US09585708B2
公开(公告)日：2017-03-07
申请号：US15014991
申请日：2016-02-03
CPC classification number: A61B18/10 , A61B18/082 , A61B18/1206 , A61B18/1233 , A61B18/1492 , A61B2017/00575 , A61B2018/00351 , A61B2018/0041 , A61B2018/00446 , A61B2018/00577 , A61B2018/00642 , A61B2018/00702 , A61B2018/0075 , A61B2018/00791 , A61B2018/00875 , A61B2218/002 , A61M25/0071 , A61N1/205
Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.
Abstract translation: 医疗器械的一些实施例可以被配置为通过在医疗过程期间将负电荷偏压递送到与血液或身体组织相接触的导电表面来减少凝结物的形成。 在仪器 - 血液界面处应用负电荷可以减少纤维蛋白原沉积和凝结物的形成，因为纤维蛋白原分子通常在中性pH水平下带负电荷。 此外，仪器的一些实施例可以被配置为用RGD / ClfA肽，碳酸氢盐溶液（或其它高pH溶液）或两者冲洗仪器 - 血液界面，以进一步排斥纤维蛋白原，从而抑制凝块的形成。 因此，医疗器械的一些实施例可以显着降低特定医疗过程中血栓栓塞的风险。
-
公开(公告)号：US20140324040A1
公开(公告)日：2014-10-30
申请号：US14330671
申请日：2014-07-14
Inventor： Samuel J. Asirvatham , Arshad Jahangir , Bernard B.C. Lim , Kalpathi L. Venkatachalam
CPC classification number: A61B18/10 , A61B18/082 , A61B18/1206 , A61B18/1233 , A61B18/1492 , A61B2017/00575 , A61B2018/00351 , A61B2018/0041 , A61B2018/00446 , A61B2018/00577 , A61B2018/00642 , A61B2018/00702 , A61B2018/0075 , A61B2018/00791 , A61B2018/00875 , A61B2218/002 , A61M25/0071 , A61N1/205
Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.
Abstract translation: 医疗器械的一些实施例可以被配置为通过在医疗过程期间将负电荷偏压递送到与血液或身体组织相接触的导电表面来减少凝结物的形成。 在仪器 - 血液界面处应用负电荷可以减少纤维蛋白原沉积和凝结物的形成，因为纤维蛋白原分子通常在中性pH水平下带负电荷。 此外，仪器的一些实施例可以被配置为用RGD / ClfA肽，碳酸氢盐溶液（或其它高pH溶液）或两者冲洗仪器 - 血液界面，以进一步排斥纤维蛋白原，从而抑制凝块的形成。 因此，医疗器械的一些实施例可以显着降低特定医疗过程中血栓栓塞的风险。
-
-
-
Search Results
4
records
(took 0.014 seconds)
